SOCIAL MEDIA IMPACT of ASCO 2023

Jun 30, 2023 12:15:22 PM

The 2023 ASCO (American Society of Clinical Oncology) annual meeting took place from June 2nd to June 6th, 2023, in Chicago, Il, USA. This year’s event was primarily an in-person event with virtual broadcasts available. The program at a glance is available here. As has been the case since 2019 we will be assessing the impact of the conference online:

From the view of HCPs:

Conditions and drugs most discussed during the listening period
Posts that generated the most engagement
Focus on multiple myeloma

From the view of pharma companies:

Top pharma companies (in terms of mentions)

Scope

The scope of the analysis is focused on mentions coming worldwide.*

A total of 86K mentions were recorded during the listening period from May 26th, 2023, to June 20th, 2023 (one week before and two weeks after the conference).

All mentions came from Twitter.

A total of 13K unique authors were identified.

*#asco23 OR #asco2023 OR (asco NEAR/2 (2023 OR 23))

 Methodology

**#asco23 OR #asco2023 OR (asco NEAR/2 (2023 OR 23))

Volume of conversations

There was a slight decrease in overall mentions of 1,74% when compared to ASCO 2022, with HCPs representing the bulk of conversations at 78%. As usual, the peak of conversations happened during the conference, representing 68% of mentions recorded during the listening period.

Volume of conversations

Top hashtags

The top hashtag was

#lcsm
(lung cancer social media).

This list is in line with the most discussed diseases during the conference namely lung and breast cancers as well as
multiple myeloma.

SOV Product and cancer type amongst HCPs

SOV products

SOV cancer type

Note: Stomach, Carcinoma of unknown primary, Head and neck cancer, Esophageal, Bile duct cancer, Skin, Thymic, Blood cancers at less than 1%

KEYTRUDA (pembrolizumab)

Keynote 671 was of particular interest to HCPs, showing improved event free survival as well as a reduced risk of disease recurrence, progression or death by 42% in resectable stage II, IIIA or IIIB non-small cell lung cancer.

Type of cancer mentioned:

engagement (2)

OPDIVO (nivolumab)

Several results from clinical trials in RCC cancer were presented. Of note checkmate 914 reporting subgroup analyses benefiting some RCC patients. Other clinical trial mentioned include checkmate 214 and checkmate 9ER.

Type of cancer mentioned:
cancer mentioned (2)

TAGRISSO (osimertinib)

The main news when it comes to TAGRISSO comes from the ADAURA trial which showed improved survival in resected EGFR mutated NSCLC. Results were deemed groundbreaking, impressive and reinforcing adjuvant osimertinib as a standard of care for patients with stage IB to IIIA EGFR-mutated NSCL.

Type of cancer mentioned:

Focus on multiple myeloma

This year’s edition was heavily focused on CAR-T cell therapies and bispecific antibodies.

Highly anticipated results from the CARTITUDE-4 reflect this. Other development of note include teclistamab and talquetamab and corresponding trials RedirecTT-1 and MajesTEC-1.

Topics of discussions (type of treatment)